pharmaphorum

AUGUST 2, 2022

The trial involved cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who were getting treatment with Tecentriq second-line after earlier platinum-based chemotherapy failed. Results from a trial in first-line NSCLC are due in early 2023.

Chemotherapy 105

Chemotherapy FDA 105

pharmaphorum

SEPTEMBER 13, 2022

While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century. 1942 – Chemotherapy moves from trenches to treatment .

Chemotherapy 98

Chemotherapy Immunization FDA Documentation 98

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. billion in 2028. This announcement is not the only recent development for Keytruda.

Chemotherapy 52

Chemotherapy Packaging FDA Documentation 52

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Chemotherapy 59

Chemotherapy Immunization FDA 59

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Tivdak, a tissue-factor targeting ADC that was developed in collaboration with Genmab, was approved in 2021.

Chemotherapy 59

Chemotherapy Compounding FDA 59

Roots Analysis

OCTOBER 4, 2023

During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy.

Chemotherapy 40

Chemotherapy Immunization FDA 40

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Chemotherapy 52

Chemotherapy Labelling FDA Communication 52